Recent Research Analysts’ Ratings Changes for Kodiak Sciences (KOD)

Kodiak Sciences (NASDAQ: KOD) recently received a number of ratings updates from brokerages and research firms:

• 9/30/2026 – Kodiak Sciences had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $103.00 price target on the stock.
• 9/28/2026 – Kodiak Sciences had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $112.00 price target on the stock.
• 9/28/2026 – Kodiak Sciences had its price target raised by Lifesci Capital from $85.00 to $145.00. They now have an “outperform” rating on the stock.
• 9/28/2026 – Kodiak Sciences had its price target raised by UBS Group AG from $80.00 to $120.00. They now have a “buy” rating on the stock.
• 9/28/2026 – Kodiak Sciences had its price target raised by HC Wainwright from $58.00 to $96.00. They now have a “buy” rating on the stock.
• 9/26/2026 – Kodiak Sciences was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 9/24/2026 – Kodiak Sciences is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $36.00 price target on the stock.
• 9/24/2026 – Kodiak Sciences is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $36.00 price target on the stock.
• 9/17/2026 – Kodiak Sciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $58.00 price target on the stock.
• 8/17/2026 – Kodiak Sciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $58.00 price target on the stock.
• 8/15/2026 – Kodiak Sciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/3/2026 – Kodiak Sciences had its price target raised by JPMorgan Chase & Co. from $56.00 to $66.00. They now have an “overweight” rating on the stock.

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.